CCCC
- C4 Therapeutics, Inc.
()
Overview
Company Summary
C4 Therapeutics, Inc. is a biotechnology company that focuses on developing and commercializing innovative medicines to treat various diseases. Their primary area of expertise lies in targeted protein degradation, a novel approach that aims to remove disease-causing proteins from the body.
The company's platform technology, called Degronimid�, allows for the targeted destruction of specific proteins involved in disease pathways. Degradation of these proteins can be beneficial in various therapeutic areas, including oncology, neurodegenerative disorders, immunology, and metabolic diseases.
C4 Therapeutics designs and develops small molecule drugs that can selectively and efficiently degrade disease-causing proteins. By harnessing the body's natural protein quality control system, these drugs can potentially provide more effective treatments for a range of diseases.
The company's drug development process involves advancing multiple programs through preclinical and clinical stages to identify promising candidates for further development. They collaborate with strategic partners, including pharmaceutical companies, academic institutions, and other biotechnology organizations, to accelerate the discovery and development of their therapies.
C4 Therapeutics aims to bring transformative therapies to patients and improve their quality of life by targeting the root causes of diseases. Through their innovative protein degradation approach, they strive to address significant unmet medical needs and deliver breakthrough treatments in various disease areas.